Fulgent Genetics (NASDAQ:FLGT) Releases FY 2025 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of -0.650–0.650 for the period, compared to the consensus estimate of -0.460. The company issued revenue guidance of $310.0 million-$310.0 million, compared to the consensus revenue estimate of $324.2 million. Fulgent Genetics also updated its FY25 guidance to $(0.65) EPS.

Fulgent Genetics Trading Down 1.5 %

Shares of FLGT stock opened at $15.45 on Friday. Fulgent Genetics has a 1 year low of $15.21 and a 1 year high of $25.11. The firm’s fifty day simple moving average is $17.32 and its 200 day simple moving average is $19.49. The firm has a market capitalization of $472.57 million, a P/E ratio of -2.80 and a beta of 1.39.

Wall Street Analyst Weigh In

FLGT has been the topic of several analyst reports. Piper Sandler lowered their price target on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th. StockNews.com lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.